Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)

South Korea flag South Korea · Delayed Price · Currency is KRW
15,680
-1,120 (-6.67%)
At close: Feb 27, 2026
154.55%
Market Cap 1.51T
Revenue (ttm) 1.96B
Net Income (ttm) -21.96B
Shares Out 96.04M
EPS (ttm) -183.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,182,262
Average Volume 7,530,009
Open 16,180
Previous Close 16,800
Day's Range 14,570 - 17,200
52-Week Range 4,325 - 21,500
Beta 0.93
RSI 63.26
Earnings Date Mar 18, 2026

About Hyundai Bioscience

Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 2000
Employees 69
Stock Exchange KOSDAQ
Ticker Symbol 048410
Full Company Profile

Financial Performance

In 2024, Hyundai Bioscience's revenue was 15.05 billion, an increase of 58.73% compared to the previous year's 9.48 billion. Losses were -6.93 billion, -52.21% less than in 2023.

Financial Statements

News

There is no news available yet.